Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Non-Current Assets (2018 - 2026)

10x Genomics' Non-Current Assets history spans 8 years, with the latest figure at $356.9 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 6.78% to $356.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a 0.87% decrease, with the full-year FY2025 number at $356.9 million, up 6.78% from a year prior.
  • Non-Current Assets hit $356.9 million in Q4 2025 for 10x Genomics, down from $367.5 million in the prior quarter.
  • Over the last five years, Non-Current Assets for TXG hit a ceiling of $412.1 million in Q1 2023 and a floor of $208.3 million in Q1 2021.
  • Historically, Non-Current Assets has averaged $334.0 million across 5 years, with a median of $347.2 million in 2024.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 75.02% in 2021 and later decreased 13.81% in 2024.
  • Tracing TXG's Non-Current Assets over 5 years: stood at $271.2 million in 2021, then surged by 45.24% to $393.9 million in 2022, then fell by 6.3% to $369.1 million in 2023, then fell by 9.45% to $334.2 million in 2024, then grew by 6.78% to $356.9 million in 2025.
  • Business Quant data shows Non-Current Assets for TXG at $356.9 million in Q4 2025, $367.5 million in Q3 2025, and $324.3 million in Q2 2025.